… eltrombopag).[11] There was no evidence of rebound thrombocytopenia after ceasing
eltrombopag … within the normal range at baseline and were unaffected by eltrombopag …

… eltrombopag … of eltrombopag than in the other eltrombopag groups. After 1 week of treatment
(day 8), more than 10% of patients in the groups receiving 50 mg or 75 mg of eltrombopag …

… to once daily eltrombopag versus … eltrombopag needed rescue treatment compared with
25 (40%) patients receiving placebo (p=0·001). Three (2%) patients receiving eltrombopag had …

Background A single-group, phase 1–2 study indicated that eltrombopag improved the
efficacy of standard immunosuppressive therapy that entailed horse antithymocyte globulin (ATG) …

… Proliferation and differentiation induced by eltrombopag. a Proliferation of BAF3/hTpoR
cells induced by eltrombopag after 48 h of treatment; the dotted line represents the activity of …

Background Eltrombopag is an oral, non-peptide, thrombopoietin-receptor agonist that
stimulates thrombopoiesis, leading to increased platelet production. This study assessed the …

… Eltrombopag increases and maintains hemostatic platelet counts; however, to date, … EXTEND
(Eltrombopag eXTENded Dosing) study evaluates the safety and efficacy of eltrombopag in …

… the experience reported using eltrombopag in ITP, … of eltrombopag in particular situations
will also be covered. The experience reported so far permits us to suggest that eltrombopag …

… Eltrombopag (Promacta) is an oral thrombopoietin mimetic … Eltrombopag increases platelet
counts in healthy persons and … We hypothesized that eltrombopag might have activity in …

… Eltrombopag is an oral thrombopoietin-receptor agonist. This study evaluated the efficacy
of eltrombopag for increasing platelet counts and reducing the need for platelet transfusions in …